| Expression pattern: |
DN |
| Associated gene: |
CAV1, AGO2 |
| Associated microRNA: |
miR-6792-3p |
| Biological function: |
tumor suppressor; inhibits proliferation; inhibits migration; inhibits invasion; inhibits tumor growth and metastasis |
| Molecular mechanism: |
Acts as a ceRNA/miRNA sponge for miR-6792-3p to relieve repression of CAV1. |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); ceRNA regulation (promotes); Wnt/beta-catenin (inhibits); cell cycle (inhibits); EMT (inhibits) |
| Detected method: |
Q
H
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; FISH / smFISH; ISH (In Situ Hybridization); RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Wound Healing Assay; Transwell Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Clinical Sample Validation; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Low circCCDC9 expression correlates with larger tumor size, lymph node invasion, advanced clinical stage, and shorter overall survival; high circCCDC9 predicts longer OS and DFS. |
| Description: |
circCCDC9 (hsa_circ_0000944), derived from CCDC9, is down-regulated in gastric cancer and mainly localized in the cytoplasm. It suppresses GC cell proliferation, migration, invasion, tumor growth and liver metastasis by sponging miR-6792-3p and de-repressing CAV1, and higher circCCDC9 expression is associated with better OS/DFS. |
| Confidence score: |
0.8892 |